Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the ...

Subcutaneous anifrolumab significantly reduces disease activity in patients with moderate to severe systemic lupus erythematosus.

Positive full results from AstraZeneca’s Phase III TULIP-SC trial have shown the subcutaneous (SC) administration of Saphnelo ...

Positive full results from the Phase III TULIP-SC trial showed the subcutaneous administration of Saphnelo demonstrated a statistically ...

Positive full results from the Phase III TULIP-SC trial showed the subcutaneous (SC) administration of Saphnelo (anifrolumab) demonstrated a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio PHILADELPHIA — Belimumab demonstrated a ...

A systematic review and meta-analysis presented at ACR Convergence 2022 provide insight into the effects of belimumab in patient populations with cutaneous lupus erythematosus, with or without ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Treatment with ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and ...

Lupus erythematosus is a heterogeneous autoimmune disorder that frequently manifests with distinctive cutaneous involvement. The cutaneous lesions, which range from a malar rash to more indurated, ...

In a new letter, published in the Journal of the European Academy of Dermatology and Venereology, members of the lupus community underscore the critical need to recognize the unique challenges of ...

Please provide your email address to receive an email when new articles are posted on . 38% of patients with cutaneous lupus erythematosus displayed evidence of positive interferon (IFN)-alpha ...